



MedAutonomic Undertakes the First Digestive Endoscopic Implant of a Brain Neuromodulation Device

Contacts

Paolo Fabris (Italy)
+39 346 3245963
paolo.fabris@medautonomic.com

John Gonzales (USA)
(415) 377-5653
john.gonzales@medautonomic.com

Concord, CA – March 8, 2017 – MedAutonomic, a Silicon Valley and Venice, Italy-based medtech company has successfully implanted a brain neuromodulation device, the Phoenix, into the stomach wall of a swine through a digestive endoscopic procedure. The Phoenix is a bioelectric medicine that is powered without a battery. It sends signals to the brain (the limbic system) to adjust an imbalance in the Autonomic Nervous System in order to treat functional diseases such as type-2 diabetes, hypertension, and gastroesophageal reflux disease (GERD).

According to MedAutonomic president Dr. Valerio Cigaina, who is spearheading the research, “Our initial results on swine are very promising. The outpatient procedure using a gastric endoscope has been perfected, and we are able to implant our device without surgery in less than five minutes. The prototype Phoenix is sending a signal to the brain, and heart rate variability (HRV) is being significantly increased, gaining a high parasympathetic tone. As the brain-gut axis of swine is similar to that of humans, we expect to find similar results when we do the first human implant in the coming months.”

“The technology that we have developed to generate power without a battery to send a signal to the brain is important” said Paolo Fabris, chief executive officer of MedAutonomic. “We are able to harvest energy from the body, so the device can remain in the stomach wall without the need to replace a battery. We plan to do the first human implant by the end of 2017, followed by the start of the CE mark trials.”

About MedAutonomic

MedAutonomic is a privately held medtech company dedicated to developing a bioelectric medicine to treat patients with functional diseases of the metabolic syndrome such as type-2 diabetes, hypertension and gastroesophageal reflux disease (GERD). MedAutonomic’s approach is to offer a nonsurgical alternative treatment of functional diseases with a lower cost compared to drug therapy and traditional surgical procedures.

MedAutonomic’s Brain NeuroModulation (BNM) device, the Phoenix, is implanted with a digestive endoscope and power is generated without a battery. The device sends a signal directly to the brain correcting an imbalance in the Autonomic Nervous System. For more information, visit www.medautonomic.com.